School of Medicine
Showing 321-330 of 418 Results
-
Aditya Srivatsan
Affiliate, Department Funds
Resident in Neurology & Neurological SciencesBioStanford Neurology Physician Resident, PGY-3
-
Kristen K. Steenerson, MD
Clinical Associate Professor, Otolaryngology (Head and Neck Surgery)
Clinical Assistant Professor, Adult NeurologyBioKristen K. Steenerson, MD is a board-certified neurologist with fellowship training in vestibular neurology. She graduated cum laude from Claremont McKenna College, received her MD from the University of Utah, completed neurology residency at Mayo Clinic Arizona, and fellowship at Barrow Neurological Insitute. She directs the Vestibular Balance Disorders Program of the Stanford Balance Center. She has joint appointments in the departments of Otolaryngology--Head and Neck Surgery and Neurology & Neurological Sciences at Stanford. Her clinical interests include vestibular migraine, benign paroxysmal positional vertigo, Ménière's disease, and international neurology.
-
Gary K. Steinberg, MD, PhD
Bernard and Ronni Lacroute-William Randolph Hearst Professor of Neurosurgery and Neurosciences and Professor, by courtesy, of Neurology and Neurological Sciences
Current Research and Scholarly InterestsOur laboratory investigates the pathophysiology and treatment of cerebral ischemia, and methods to restore neurologic function after stroke. Treatment strategies include brain hypothermia, stem cell transplantation and optogenetic stimulation. Our clinical research develops innovative surgical, endovascular and radiosurgical approaches for treating difficult intracranial aneurysms, complex vascular malformations and occlusive disease, including Moyamoya disease, as well as stem cell transplant.
-
Lawrence Steinman, MD
George A. Zimmermann Professor and Professor of Pediatrics
Current Research and Scholarly InterestsOur laboratory is dedicated to understanding the pathogenesis of autoimmune diseases, particularly multiple sclerosis. We have developed several new therapies for autoimmunity, including some in Phase 2 clinical trials, as well as one approved drug, natalizumab. We have developed microarray technology for detecting autoantibodies to myelin proteins and lipids. We employ a diverse range of molecular and celluar approaches to trying to understand multiple sclerosis.
